Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2004 Jun 14;90(12):2317-25.
doi: 10.1038/sj.bjc.6601879.

Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

A O'Donnell  1 , I Judson, M Dowsett, F Raynaud, D Dearnaley, M Mason, S Harland, A Robbins, G Halbert, B Nutley, M Jarman
Affiliations
Clinical Trial

Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

A O'Donnell et al. Br J Cancer. .

Abstract

A series of three dose escalating studies were conducted to investigate the ability of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate, to cause maximum suppression of testosterone synthesis when delivered to castrate and noncastrate males with prostate cancer. Study A was a single dose study in castrate males. Study B was a single dose study in noncastrate males and study C was a multiple dose study in noncastrate males. The drug was given orally in a once-daily dose and blood samples taken to assess pharmacokinetic (PK) parameters and hormone levels in all patients. The study drug was well tolerated with some variability in PKs. Suppression of testosterone levels to <0.14 nmol l(-1) was seen in four out of six castrate males treated with a single dose of 500 mg. At 800 mg given days 1-12 in noncastrate males, target suppression was achieved in three out of three patients, but a two- to three-fold increase of Luteinising Hormone (LH) levels in two out of three patients overcame suppression within 3 days. All patients in the multiple dose study developed an abnormal response to a short Synacthen test by day 11, although baseline cortisol levels remained normal. This is the first report of the use of a specific 17alpha-hydroxylase/(17,20)-lyase inhibitor in humans. Repeated treatment of men with intact gonadal function with abiraterone acetate at a dose of 800 mg can successfully suppress testosterone levels to the castrate range. However, this level of suppression may not be sustained in all patients due to compensatory hypersecretion of LH. The enhanced testosterone suppression achieved in castrate men merits further clinical study as a second-line hormonal treatment for prostate cancer. Adrenocortical suppression may necessitate concomitant administration of replacement glucocorticoid.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Steroid synthesis pathway. DHEA=dehydroepiandrosterone; 5αred=5αreductase; DHT=dihydrotestosterone.
Figure 2
Figure 2
Abiraterone structure. R=H: abiraterone (CB7598); R=Ac: abiraterone acetate (CB7630).
Figure 3
Figure 3
Selected mean hormone levels in castrate men receiving a single dose of abiraterone acetate.
Figure 4
Figure 4
Serial hormone levels in noncastrate patients treated with a single oral dose of abiraterone acetate.
Figure 5
Figure 5
Serial hormone levels in noncastrate patients treated with multiple oral doses of abiraterone acetate.
Figure 6
Figure 6
Relationship between dose and AUC for abiraterone acetate given orally for all three studies. R2=linear regression coefficient; AUC: area under the dose/concentration curve.
See this image and copyright information in PMC

References

    1. Barrie SE, Haynes BP, Potter GA, Chan FCY, Goddard PM, Dowsett M, Jarman M (1997) Biochemistry and Pharmacokinetics of Potent Non-steroidal Cytochrome P45017α Inhibitors. J Steroid Biochem Mol Biol 60(5/6): 347–351 - PubMed
    1. Barrie SE, Potter GA, Goddard PM, Haynes BP, Dowsett M, Jarman M (1994) Pharmacology of novel steroidal inhibitors of cytochrome P45017α (17α-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol 50(5/6): 267–273 - PubMed
    1. Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser T, Willi N, Mihatsch M, Sauter G, Kallioniemi O (1999) Survey of gene amplifications during prostate cancer progression by high-throughput fluorescence in situ hybridization on tissue microarrays. Cancer Res 59: 803–806 - PubMed
    1. Cancer Research UK (2002) Combined statistics from Mortality Statistics Cause DH 2 Nat Stat (Eng & W), Registrar General for Scotland Annual Report, Registrar General for Nth Ire Annual Report May 2002
    1. DeMario MD, Ratain MJ (1998) Oral chemotherapy: rationale and future directions. J Clin Oncol 16(7): 2557–2567 - PubMed